Clinical Trials Browser

Lymphoma, Large B-Cell, Diffuse × Prednisone × 90 days × Clear all

NCT06649812 2026-04-16

Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma

Phase 2 Recruiting

Lymphoma, Large B-Cell, Diffuse

NCT06717347 2026-04-16

MK-2140-010

Phase 3 Recruiting

Lymphoma, Large B-Cell, Diffuse

NCT04978584 2026-04-15

Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study

Phase 2 Active not recruiting

Lymphoma, Large B-Cell, Diffuse

NCT04799275 2026-04-14

Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma

Phase 2/3 Suspended

Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

NCT03984448 2026-04-13

Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas

Phase 2/3 Active not recruiting

Lymphoma, Large B-Cell, Diffuse

NCT05283720 2026-04-13

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

Phase 2 Recruiting

LymphoidOther hematologic neoplasm

Leukemia, Hairy Cell, Lymphoma, Non-Hodgkin, Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT04231448 2026-04-08

DEB

Phase 3 Completed

Lymphoma, Large B-Cell, Diffuse

NCT04542824 2026-04-08

EPCORE™ NHL-3

Phase 1/2 Active not recruiting

LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

NCT04663347 2026-04-08

EPCORE™ NHL-2

Phase 1/2 Active not recruiting

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

NCT06890884 2026-04-02

MK-2140-011

Phase 2 Recruiting

Lymphoma, Large B-Cell, Diffuse

NCT03223610 2026-04-01

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma

Phase 1/2 Recruiting

Burkitt Lymphoma, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT04824092 2026-04-01

frontMIND

Phase 3 Active not recruiting

Lymphoma, Large B-Cell, Diffuse

NCT04529772 2026-03-31

ESCALADE

Phase 3 Active not recruiting

Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Neoplasms, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT07493148 2026-03-25

Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL

Phase 2 Recruiting

Lymphoma, Large B-Cell, Diffuse

NCT02213913 2026-03-11

Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas

Phase 1/2 Completed

55 enrolled 17 charts

LymphoidOther hematologic neoplasm

Hodgkin Disease, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Intraocular Lymphoma

NCT05800366 2026-03-05

A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma

Phase 2 Recruiting

Lymphoma, Lymphoma, Large B-Cell, Diffuse

NCT04231877 2026-03-03

Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma

Phase 1 Recruiting

Lymphoma, Large B-Cell, Diffuse

NCT04739813 2026-02-24

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma

Phase 1 Recruiting

Burkitt Lymphoma, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT05389423 2026-02-19

Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas

Phase 1 Recruiting

Plasmablastic Lymphoma, Burkitt Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Epstein-Barr Virus Infections

NCT03274492 2026-02-06

POLARIX

Phase 3 Active not recruiting

1,000 enrolled 2 FDA

Lymphoma, Large B-Cell, Diffuse

NCT03749018 2026-02-06

Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma

Phase 2 Active not recruiting

Lymphoma, Large B-Cell, Diffuse

NCT04850495 2026-02-06

Zanubrutinib in Combination With R-PolaCHP (ZaR-PolaCHP) for Newly Diagnosed Diffuse Large B-Cell Lymphoma

Phase 1 Suspended

Lymphoma, Large B-Cell, Diffuse

NCT06091865 2026-02-05

OLYMPIA-3

Phase 3 Active not recruiting

Lymphoma, Large B-Cell, Diffuse

NCT06594939 2026-02-04

Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma

Phase 2 Not yet recruiting

Lymphoma, Large B-Cell, Diffuse

NCT04323956 2026-02-02

Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma

Phase 1 Active not recruiting

Lymphoma, Large B-Cell, Diffuse

NCT03943901 2026-01-29

Split-Dose R-CHOP for Older Adults With DLBCL

Phase 2 Active not recruiting

27 enrolled 11 charts

Lymphoma, Neoplasms, Lymphoma, Large B-Cell, Diffuse